Parabilis

Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug zolucatetide. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…

Kyle LaHucik · 2026-06-10

Despite all the noise around upcoming massive IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest Nasdaq debut the biopharma industry has ever seen. On ...

Source: Endpoints News